Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BAZ2A | Q9UIF9 | 2/20 | 0.51 |
| ▸ | RAB9A | P51151 | 6/20 | 0.50 |
| ▸ | NPC1 | O15118 | 5/20 | 0.50 |
| ▸ | MAPT | P10636 | 4/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | CASP3 | P42574 | 1/20 | 0.50 |
| ▸ | CASP7 | P55210 | 1/20 | 0.50 |
| ▸ | CASP8 | Q14790 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.43 |
| ▸ | PLAT | P00750 | 2/20 | 0.43 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1228518 | 0.99 | BAZ2A (0.52) | BAZ2ARAB9ANPC1MAPTALDH1A1 | |
| Hydrochloric Acid SCHEMBL1119928 | 0.97 | RAB9A (0.53) | BAZ2ARAB9ANPC1MAPTALDH1A1 | |
| SCHEMBL2142237 | 0.89 | RAB9A (0.57) | RAB9ANPC1MAPTALDH1A1CASP3 | |
| Tert-Butyl Formate SCHEMBL27649859 | 0.88 | BAZ2A (0.46) | BAZ2ARAB9ANPC1MAPTALDH1A1 | |
| SCHEMBL2142696 | 0.87 | SMN1; SMN2 (0.56) | RAB9ANPC1MAPTALDH1A1CASP3 | |
| SCHEMBL1245930 | 0.87 | SMN1; SMN2 (0.60) | RAB9ANPC1MAPTALDH1A1CASP3 | |
| SCHEMBL996638 | 0.85 | SMN1; SMN2 (0.62) | RAB9ANPC1MAPTALDH1A1CASP3 | |
| SCHEMBL3435708 | 0.84 | RAB9A (0.52) | RAB9ANPC1MAPTALDH1A1CASP3 | |
| SCHEMBL17885697 | 0.84 | RAB9A (0.52) | RAB9ANPC1MAPTALDH1A1CASP3 | |
| SCHEMBL31705780 | 0.84 | PLAT (0.45) | BAZ2AMAPTCASP3CASP7CASP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080306114-A1 | Human G Protein-Coupled Receptor and Modulators Thereof for the Treatment of Hyperglycemia and Related Disorders | ARENA PHARMACEUTICALS, INC (US) | 2008-12-11 | — | — | US | disclosed |
| US-20070231263-A1 | Human G protein-coupled receptor and modulators thereof for the treatment of hyperglycemia and related disorders | ARENA PHARMACEUTICALS, INC. | 2007-10-04 | — | — | US | disclosed |
| EP-1735622-A2 | MODULATORS OF HUMAN G PROTEIN-COUPLED RECEPTORS FOR THE TREATMENT OF HYPERGLYCEMIA AND RELATED DISORDERS | Arena Pharmaceuticals, Inc. (US) | 2006-12-27 | — | — | EP | disclosed |
| WO-2005116653-A2 | MODULATORS OF HUMAN G PROTEIN-COUPLED RECEPTORS FOR THE TREATMENT OF HYPERGLYCEMIA AND RELATED DISORDERS | ARENA PHARMACEUTICALS, INC. (US) | 2005-12-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070231263-A1 | Human G protein-coupled receptor and modulators thereof for the treatment of hyperglycemia and related disorders | GPR119, GCGR, GLP1R | BAZ2A 2420/4885RAB9A 1515/4885NPC1 1246/4885 |
| US-20080306114-A1 | Human G Protein-Coupled Receptor and Modulators Thereof for the Treatment of Hyperglycemia and Related Disorders | GPR119, GCGR, GLP1R | BAZ2A 2420/4885RAB9A 1515/4885NPC1 1246/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.